PhaseRx, Inc. (NASDAQ: PZRX), a Seattle-based biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, has filed a chapter 11 petition before the United States Bankruptcy Court for the District of Delaware (Case No. 17-12890).  The case has been assigned to the Honorable Christopher S. Sontchi.  The petition indicates assets of $4.1 million and liabilities of $5.6 million.  Donlin Recano will serve as the claims agent.  The company has issued a press release regarding its reorganization.


Contact Norman L. Pernick or Nicholas J. Brannick for more information regarding this matter.  Please note, however, that Cole Schotz P.C. does not represent the debtors in these cases and cannot respond to questions directed toward the debtors.